ISO/TS 10993-20:2006

Overview

ISO/TS 10993-20:2006 - "Biological evaluation of medical devices - Part 20: Principles and methods for immunotoxicology testing of medical devices" - provides a practical framework for evaluating the potential immunotoxicity of medical devices. As a Technical Specification in the ISO 10993 series, it summarizes the current state of immunotoxicology, outlines hazard identification and risk‑management principles, and gives guidance on available in vivo and in vitro methods. The document emphasizes that it is a guidance framework rather than a set of prescriptive standardized tests.

Key topics

• Scope & intent: Overview of immunotoxicology specific to medical devices and materials (polymers, metals, ceramics, biologicals).
• Risk assessment and management: Integration with ISO 14971 for hazard identification, dose–response and exposure assessment, and risk control measures.
• Hazard identification: Importance of material characterization, residue and leachable analysis, additives, exposure route and duration, and prior clinical experience.
• Types of immune effects: Guidance on assessing inflammation (acute and chronic), immunosuppression, immunostimulation, hypersensitivity (Type I, Type IV), and autoimmunity.
• Testing approaches: Use and limitations of in vivo assays and the supplemental role of in vitro mechanistic studies.
• Data extrapolation: Considerations for translating preclinical immunotoxicity data to human risk.
• Informative annexes: current state of knowledge, clinical experience summaries, and a testing flow chart.

Applications

ISO/TS 10993-20 is used to:

• Guide selection of immunotoxicology assessment strategies during device development and preclinical evaluation.
• Inform regulatory submissions and safety dossiers where immune interactions are a concern.
• Support design decisions to reduce immunogenic components (e.g., additives, leachables). Practical steps encouraged by the TS include performing literature searches for known immunotoxic agents, characterizing materials and leachables, assessing exposure route/duration, and applying risk management measures (labeling, design changes, restrictions).

Who should use this standard

• Medical device manufacturers (R&D, biocompatibility teams)
• Regulatory affairs and quality assurance professionals
• Toxicologists, immunotoxicologists and contract testing laboratories
• Clinical safety assessors and notified bodies reviewing biological evaluation

Related standards

• ISO 10993-1 (biological evaluation framework)
• ISO 10993-10, -11, -6 (irritation, systemic toxicity, implantation)
• ISO 14971 (risk management for medical devices)

Keywords: ISO/TS 10993-20, immunotoxicology testing, medical devices, biological evaluation, immunotoxicity, leachables, risk assessment, ISO 10993.